organization · Reporting owner
Xi Long USA, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | 10% owner | September 30, 2016 | October 04, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 30, 2016 · Filed October 04, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Issuer Common StockSEC Table I · non-derivative | Direct | 2,025,623 |
Reported balance
After 2016-09-30 transaction · row 1
1 source rowRow 1 · 2016-09-30 · Other · Acquired 2,025,623 · Balance 2,025,623 F1: The securities were received in the Reorganization (as defined below), a transaction exempt under Rule 16b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in exchange for the cancellation of 15,394,737 Class D-2 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). |
| Predecessor Class D-2 Preferred UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-30 · Other · Disposed 15,394,737 · Balance 0 F2: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-2 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1. F3: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof. F4: The securities were disposed of and cancelled in the Reorganization, a transaction exempt under Rule 16b-7 under the Exchange Act, in exchange for 2,025,623 shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were received in the Reorganization (as defined below), a transaction exempt under Rule 16b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in exchange for the cancellation of 15,394,737 Class D-2 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC").
F2: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-2 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.
F3: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof.
F4: The securities were disposed of and cancelled in the Reorganization, a transaction exempt under Rule 16b-7 under the Exchange Act, in exchange for 2,025,623 shares of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2016 Filed Oct 4, 2016 18:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | OtherPredecessor Class D-2 Preferred Units · Derivative | 15,394,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-144640 · doc4.xml · derivative · entry 2 Xi Long USA, Inc. · CIK 0001684591 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Predecessor Class D Voting Common Units · 15,394,737 shares Expires not disclosed F2 · security: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-2 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1. F3 · derivative.exercise_price: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof. F4 · kind: The securities were disposed of and cancelled in the Reorganization, a transaction exempt under Rule 16b-7 under the Exchange Act, in exchange for 2,025,623 shares of the Issuer's common stock. F4 · price: The securities were disposed of and cancelled in the Reorganization, a transaction exempt under Rule 16b-7 under the Exchange Act, in exchange for 2,025,623 shares of the Issuer's common stock. F3 · derivative.exercise_date: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof. F3 · derivative.expiration_date: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof. F2 · derivative.underlying: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-2 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 18:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | OtherIssuer Common Stock | 2,025,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-144640 · doc4.xml · nonDerivative · entry 1 Xi Long USA, Inc. · CIK 0001684591 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025,623 F1 · kind: The securities were received in the Reorganization (as defined below), a transaction exempt under Rule 16b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in exchange for the cancellation of 15,394,737 Class D-2 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). F1 · price: The securities were received in the Reorganization (as defined below), a transaction exempt under Rule 16b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in exchange for the cancellation of 15,394,737 Class D-2 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.